In the third episode of the series with Perry N. Halkitis, PhD, MS, MPH, he discusses how human behavior as well as other factors play a significant role in repeating outbreaks.
|Videos|October 3, 2021
Dolutegravir/Lamivudine Provide HIV Suppression Through 3-Year TANGO Findings
Author(s)Kevin Kunzmann
The combination therapy's non-inferior efficacy to heavier TAF regimens may indicate a greater embrace of 2-drug regimens for people living with HIV.
Advertisement
New 3-year findings presented at
The 144-week findings from ViiV Healthcare’s TANGO trial support long-term efficacy of switching people living with HIV from a TAF regimen to the 2-dose option.
Presented by Olayemi Osiyemi, MD, President of Triple O Research Institute in West Palm Beach, the TANGO trial showed non-inferior efficacy of dolutegravir/lamivudine to TAF-based 3- or 4-drug regimens, with no confirmed virologic withdrawals in treated participants and a favorable tolerability and safety profile of patients receiving the 2-drug regimen.
In an interview with Contagion during IDWeek, Osiyemi reviewed the trial data, and discussed the value of interpreting long-term efficacy and safety for HIV virologic suppression with regimens that require fewer drugs for patients.
“I guess you have to have the right marriage—the right 2 drugs to make it work,” Osiyemi said. “If we can use the fewest number of drugs, we can eliminate long-term toxicity and drug costs.”
Advertisement
Related to this article
In the first episode of our new series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
Food expert Lynette Johnston, PhD, provides some context around the ongoing outbreak, discusses prevention, and compares 2026 food recalls with previous years.
Here is a review of glucagon-like peptide-1 receptor agonist use in people with HIV.
The Peggy Lillis Foundation will host its 17th Annual Changing the Odds Gala this month in New York City, and it will include a casino, fellowship amongst the C diff community, and an award ceremony honoring a physician-scientist, philanthropist, a researcher, and a patient advocate for their contributions to C difficile awareness, treatment, and prevention.
Resistance-guided testing targeting a single gene mutation could let clinicians safely reintroduce ciprofloxacin for the majority of gonorrhea cases still susceptible to it, sparing ceftriaxone as resistance climbs worldwide. Lao-Tzu Allan-Blitz, MD, MPH, offers insights into his work in this area.
The latest CDC numbers show a 5.4% increase of measles cases from week-to-week. This year has already become the worst for the number of measles cases in the US since the disease was declared eliminated in 2000. With the start of respiratory virus season, case numbers are expected to continue to increase significantly.
New data from the PETERPEN trial suggest that piperacillin-tazobactam may be noninferior to meropenem for early clinical outcomes in select patients with ESBL bloodstream infections, but carbapenems remain the standard of care until final mortality results are available and fully analyzed.
Advertisement
Advertisement
Trending on Contagion Live
1
US Company Recalls Thousands of Pounds of Uninspected Meat
2
Carbapenem-Sparing Therapy for ESBL Bacteremia: New Trials, Old Questions
3
Measles Update: September 25, 2026
4
How The Food Safety Surveillance Infrastructure Works in the US
5